跳轉到

Q1. Which treatment recommendation is WRONG?

  • (A) R-CHOP regimen with CNS prophylaxis is recommended in patients with primary testicular lymphoma.
  • (B) Radiation therapy to the contralateral testis is not recommended in patients with primary testicular lymphoma.
  • (C) In pregnant female with symptomatic lymphoma, full-dose CHOP during the second and third trimesters may be considered relatively safe with little risk of significant adverse fetal outcome.
  • (D) Pregnant female with supradiaphragmatic stage I DLBCL may be considered for localized radiotherapy as a temporary measure until the second trimester, when chemotherapy holds less risk for the fetus.
  • (E) Rituximab plus dose-adjusted EPOCH with radiation is considered a preferred frontline regiment for patients with primary mediastinal large B-cell lymphoma.
點此顯示正解

(B) Radiation therapy to the contralateral testis is not recommended in patients with primary testicular lymphoma.

詳解

Analysis of Board Question

1) Why (B) is the WRONG statement:

Option (B) states that "Radiation therapy to the contralateral testis is not recommended" in primary testicular lymphoma. This is incorrect because contralateral testicular irradiation is actually strongly recommended as standard prophylactic therapy in primary testicular lymphoma137[^9].

The evidence supporting contralateral testicular radiation is robust: - The landmark IELSG-10 trial demonstrated that prophylactic radiotherapy (30 Gy) to the contralateral testis completely eliminated contralateral testicular relapses (0 relapses among 47 patients who received radiation)17 - The subsequent IELSG-30 trial confirmed these findings with 25-30 Gy to the contralateral testis, with no testicular relapses observed3[^9] - Multiple retrospective studies confirm that contralateral testicular irradiation improves progression-free survival, disease-specific survival, and overall survival25 - Without prophylactic radiation, the historical contralateral testis relapse rate is approximately 15% at 3 years[^8] - A minimum dose of 30 Gy to the whole scrotum including the contralateral testicle is recommended4

2) Why the other options are TRUE (and therefore not the answer):

(A) R-CHOP with CNS prophylaxis is recommended in primary testicular lymphoma - TRUE - Primary testicular lymphoma has a high CNS relapse risk (19% at 5 years without prophylaxis)6[^8] - The IELSG-10 trial established R-CHOP with intrathecal methotrexate as standard therapy, reducing CNS relapse to 6%17 - The IELSG-30 trial used intensified CNS prophylaxis (intrathecal liposomal cytarabine plus IV high-dose methotrexate) with zero CNS relapses at 6-year follow-up3[^9] - CNS prophylaxis is considered essential in primary testicular lymphoma management6[^8]

(C) Full-dose CHOP in 2nd/3rd trimesters is relatively safe - TRUE - While I did not retrieve specific sources on this topic in my search, this statement reflects established practice that anthracycline-based chemotherapy (CHOP) can be administered during the second and third trimesters with acceptable fetal safety profiles, as organogenesis is complete after the first trimester

(D) Localized radiotherapy as temporary measure until 2nd trimester - TRUE - This reflects the principle of delaying chemotherapy until after the first trimester when possible to avoid teratogenic effects during organogenesis, while using radiation as a temporizing measure for symptomatic disease in selected cases

(E) R-EPOCH with radiation for primary mediastinal large B-cell lymphoma - TRUE - Rituximab plus dose-adjusted EPOCH (DA-EPOCH-R) with consolidative radiation therapy is an established preferred frontline regimen for primary mediastinal large B-cell lymphoma, particularly in North American practice

詳解 · 中文翻譯

1) 為什麼 (B) 是錯誤的敘述：

(B) 選項指出「不建議對對側睾丸進行放射治療」是主要睾丸淋巴瘤的治療。這是錯誤的，因為對側睾丸照射實際上強烈推薦作為主要睾丸淋巴瘤的標準預防療法137[^9]。

支持對側睾丸放射治療的證據非常充分： - 地標性 IELSG-10 試驗證明預防性放射治療（30 Gy）對對側睾丸完全消除了對側睾丸復發（接受放射治療的 47 名患者中有 0 例復發）17 - 隨後的 IELSG-30 試驗確認了對側睾丸 25-30 Gy 的這些發現，未觀察到睾丸復發3[^9] - 多項回顧性研究確認對側睾丸照射改善無進展生存期、疾病特異性生存期及總體生存期25 - 在沒有預防性放射治療的情況下，歷史上對側睾丸復發率在 3 年時約為 15%[^8] - 建議最小劑量為包括對側睾丸在內的整個陰囊 30 Gy4

2) 為什麼其他選項都正確（因此不是答案）：

(A) R-CHOP 與 CNS 預防在主要睾丸淋巴瘤中推薦 - 正確 - 主要睾丸淋巴瘤的 CNS 復發風險高（不預防時 5 年達 19%）6[^8] - IELSG-10 試驗確立了 R-CHOP 加鞘內甲氨蝶呤作為標準療法，將 CNS 復發降至 6%17 - IELSG-30 試驗使用強化 CNS 預防（鞘內脂質體阿糖胞苷加靜脈高劑量甲氨蝶呤），在 6 年隨訪時 CNS 復發為零3[^9] - CNS 預防在主要睾丸淋巴瘤管理中被認為是必不可少的6[^8]

(C) 第 2/3 孕期全量 CHOP 相對安全 - 正確 - 雖然我在搜索中未檢索到此題的特定來源，但此敘述反映了既定實踐，即蒽環類化療（CHOP）可在第二和第三孕期給予，有可接受的胎兒安全性，因為器官發生在第一孕期後完成

(D) 局部放射治療作為臨時措施至第 2 孕期 - 正確 - 這反映了在可能的情況下延遲化療至第一孕期後的原則，以避免器官發生期間的致畸作用，同時在選定病例中使用放射治療作為症狀性疾病的臨時措施

(E) R-EPOCH 加放射治療用於主要縱隔大 B 細胞淋巴瘤 - 正確 - Rituximab 加劑量調整 EPOCH (DA-EPOCH-R) 加鞏固性放射治療是主要縱隔大 B 細胞淋巴瘤的既定首選一線治療方案，特別是在北美實踐中

參考文獻 (AMA)

  1. Vitolo U, Chiappella A, Ferreri AJ, et al. First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-Chop, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2011;29(20):2766-72. doi:10.1200/JCO.2010.31.4187. PMID:21646602. ↩↩↩↩↩↩

  2. Conconi A, Chiappella A, Ferreri AJM, et al. IELSG30 Phase 2 Trial: Intravenous and Intrathecal CNS Prophylaxis in Primary Testicular Diffuse Large B-Cell Lymphoma. Blood Advances. 2024;8(6):1541-1549. doi:10.1182/bloodadvances.2023011251. PMID:38181782. ↩↩

  3. Mannisto S, Vähämurto P, Pollari M, et al. Intravenous but Not Intrathecal Central Nervous System-Directed Chemotherapy Improves Survival in Patients With Testicular Diffuse Large B-Cell Lymphoma. European Journal of Cancer (Oxford, England : 1990). 2019;115:27-36. doi:10.1016/j.ejca.2019.04.004. PMID:31082690. ↩↩↩↩↩↩

  4. Tokiya R, Yoden E, Konishi K, et al. Efficacy of Prophylactic Irradiation to the Contralateral Testis for Patients With Advanced-Stage Primary Testicular Lymphoma: An Analysis of Outcomes at a Single Institution. International Journal of Hematology. 2017;106(4):533-540. doi:10.1007/s12185-017-2274-5. PMID:28612278. ↩↩

  5. Ferreri AJ. Risk of CNS Dissemination in Extranodal Lymphomas. The Lancet. Oncology. 2014;15(4):e159-69. doi:10.1016/S1470-2045(13)70568-0. PMID:24694639. ↩↩

  6. Brouwer CL, Wiesendanger EM, van der Hulst PC, et al. Scrotal Irradiation in Primary Testicular Lymphoma: Review of the Literature and in Silico Planning Comparative Study. International Journal of Radiation Oncology, Biology, Physics. 2013;85(2):298-308. doi:10.1016/j.ijrobp.2012.06.019. PMID:22836054. ↩↩↩↩

  7. Eyre TA, Savage KJ, Cheah CY, et al. CNS Prophylaxis for Diffuse Large B-Cell Lymphoma. The Lancet. Oncology. 2022;23(9):e416-e426. doi:10.1016/S1470-2045(22)00371-0. PMID:36055310. ↩↩↩↩↩↩

Figures